MedTrace Logo

Study to Evaluate the Effectiveness of Legalon®

NCT05051527 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 362

Last updated 2025-09-30

No results posted yet for this study

Summary

This is a multinational, multicentre, prospective, non-interventional study (NIS) in non-alcoholic fatty liver disease (NAFLD) patients with concomitant metabolic syndrome treated with Legalon® combined with diet and exercise.

Conditions

  • Non-alcoholic Fatty Liver Disease (NAFLD)

Interventions

DRUG

Legalon® 140 mg

Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision

Sponsors & Collaborators

  • Meda Pharma S.p.A.

    collaborator UNKNOWN

  • Mylan Inc.

    lead INDUSTRY

Principal Investigators

  • Lee Yeong Yeh, Dr. · Department of Medicine, Hospital Universiti Sains Malaysia,16150 Kelantan Darul Naim, MALAYSIA

  • Sakkarin Chirapongsathorn, Dr. · Department of Internal Medicine, Phramongkutklao Hospital, Bangkok, 40002, Thailand

  • Marilyn Arguillas, Dr. · Davao Doctors Hospital, Davao City, Philippines 8000

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-08
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05051527 on ClinicalTrials.gov